NCT01020708View on ClinicalTrials.gov

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Ulcerative Colitis
Interventions
DRUG

mesalamine

4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily

DRUG

ALTH12-1:4

ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine

DRUG

ALTH12-2:4

ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine

Trial Locations (1)

73104

Oklahoma Foundation for Digestive Research, Oklahoma City

Sponsors
All Listed Sponsors
lead

Altheus Therapeutics, Inc.

INDUSTRY

NCT01020708 - Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis | Biotech Hunter | Biotech Hunter